ADJUVANT PUBLICATIONS & ABSTRACTS
Adjuvant data
Evidence / Adjuvant
Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
PUBLICATION: Arch Gynecol Obstet (2011) 283: 597. https://doi.org/10.1007/s00404-010-1454-9. AUTHORS: Kunz, G. SUMMARY: 44 patients had MammaPrint results and were eligible for the analysis. The results revealed a low risk result in 29 patients and a high risk result in 15 patients. Read more: Kunz_2011_Arch Gynecol Obstet._Use of a Genomic Test Read More
Metastatic Potential of T1 Breast Cancer Can Be Predicted by the 70-gene MammaPrint Signature
PUBLICATION: Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22. AUTHORS: Mook S., Knauer M., Bueno-de-Mesquita J.M., Retel V.P., Wesseling J., Linn S.C., Van't Veer L.J., Rutgers E.J. SUMMARY: The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 87% (SE 2%) and 91% (SE Read More
The Predictive Value of the 70-Gene Signature for Adjuvant Chemotherapy in Early Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2. AUTHORS: Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., van de Vijver M.J., Koornstra R.H., Bueno-de-Mesquita J.M., Linn S.C., van 't Veer L.J. ABSTRACT: Multigene assays have been developed and validated to determine the prognosis of breast cancer. In Read More
The 70-gene Prognosis Signature Predicts Early Metastasis in Breast Cancer Patients Between 55 and 70 Years of Age
PUBLICATION: Ann Oncol. 2010 Apr;21(4):717-22. doi: 10.1093/annonc/mdp388. Epub 2009 Oct 13. AUTHORS: Mook S., Schmidt M.K., Weigelt B., Kreike B., Eekhout I., van de Vijver M.J., Glas A.M., Floore A., Rutgers E.J., van 't Veer L.J. SUMMARY: The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 Read More
Clinical Application of the 70-gene Profile: The MINDACT Trial
PUBLICATION: J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222. AUTHORS: Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. SUMMARY: Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the Read More
Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort.
PUBLICATION: Clin Cancer Res. 2008 May 15;14(10):2988-93. doi: 10.1158/1078-0432.CCR-07-4723. AUTHORS: Wittner B.S., Sgroi D.C., Ryan P.D., Bruinsma T.J., Glas A.M., Male A., Dahiya S., Habin K., Bernards R., Haber D.A., Van't Veer L.J., Ramaswamy S. SUMMARY: The MammaPrint assay was originally designed to identify younger breast cancer patients at low Read More
Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)
PUBLICATION: Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. AUTHORS: Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., van't Veer L.J., van Dam F.S., Karsenberg K., Douma K.F., van Tinteren H., Peterse J.L., Wesseling J., Wu T.S., Atsma D., Rutgers E.J., Brink G., Floore A.N., Glas A.M., Roumen R.M., Read More
